Aducanumab for Alzheimer’s disease: expediting approval and delaying science | BMJ Evidence-Based Medicine

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Editorial

Aducanumab for Alzheimer’s disease: expediting approval and delaying science

Online download statistics by month:

Online download statistics by month: July 2021 to March 2024

	Abstract	Full	Pdf
Jul 2021	197	57	35
Aug 2021	86	39	20
Sep 2021	59	27	15
Oct 2021	626	36	19
Nov 2021	880	25	22
Dec 2021	258	5	9
Jan 2022	197	9	6
Feb 2022	137	4	3
Mar 2022	199	6	3
Apr 2022	187	6	0
May 2022	171	5	1
Jun 2022	208	8	6
Jul 2022	149	5	2
Aug 2022	149	4	2
Sep 2022	175	1	0
Oct 2022	189	6	1
Nov 2022	168	5	0
Dec 2022	97	2	1
Jan 2023	85	0	0
Feb 2023	100	2	1
Mar 2023	58	2	1
Apr 2023	70	3	2
May 2023	56	3	0
Jun 2023	48	3	2
Jul 2023	132	3	0
Aug 2023	81	3	2
Sep 2023	54	3	0
Oct 2023	127	6	0
Nov 2023	74	3	1
Dec 2023	85	5	4
Jan 2024	80	2	1
Feb 2024	69	1	1
Mar 2024	64	4	1
Total	5315	293	161